Search | Clinical Trials Finder

Conditions: Type 2 Diabetes, High Blood Pressure
Interventions: Polypill, Combined prescription of the individual medications; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, empagliflozin (low dose qd), Empagliflozin (high dose qd), empagliflozin (high dose bid), empagliflozin (low dose bid); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 983 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 39
States / cities: Florence, Alabama • Jonesboro, Arkansas • Lomita, California + 34 more

Conditions: Crohn's Disease, Glycogen Metabolism, Inflammatory Bowel Disease (IBD)
Interventions: Empagliflozin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Kidney Disease
Interventions: Vicadrostat, Empagliflozin, Placebo matching vicadrostat; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 37
States / cities: Huntsville, Alabama • Anaheim, California • San Dimas, California + 33 more

Conditions: Heart Failure
Interventions: Polypill, Control Rx; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Obesity, Weight Loss
Interventions: Empagliflozin Arm, Control Arm, Exercise capacity VO2 maximum determination, Exercise Challenge; Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Diabetes Mellitus, Type 2, Hyperglycemia
Interventions: Metformin 500 mg bid, Metformin 1000 mg bid, Empagliflozin low dose qd, Empagliflozin high dose qd, Empagliflozin low dose bid, Empagliflozin high dose bid; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 41
States / cities: Birmingham, Alabama • Manley Hot Springs, Alaska • Glendale, Arizona + 33 more

Conditions: Type 2 Diabetes
Interventions: Empagliflozin 25 MG, Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 30 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: high dose FDC, BI 10773 high dose, high dose FDC placebo, low dose FDC placebo, high dose BI 10773 placebo, low dose FDC, BI 10773 low dose, linagliptin, linagliptin placebo, BI 10773 low dose placebo, low dose BI 10773 placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 112
States / cities: Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 90 more

Conditions: Non-diabetic Chronic Kidney Disease
Interventions: Empagliflozin, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: Empagliflozin + Potassium Chloride, Empagliflozin + Potassium Nitrate, Potassium Chloride + Placebo for Empagliflozin; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Heart Failure
Interventions: Empagliflozin, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 3,730 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 92
States / cities: La Mesa, California • Long Beach, California • Los Angeles, California + 81 more

Conditions: Diabetes Mellitus, Type 2
Interventions: BI 10773, Metformin, Sitagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 12
States / cities: Mission Viejo, California • Spring Valley, California • Walnut Creek, California + 9 more

Conditions: Type 2 Diabetes
Interventions: Empagliflozin 25 MG; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 30 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type2 Diabetes, Insulin Sensitivity
Interventions: Empagliflozin 25 MG; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo identical to BI 10773 high dose, Placebo identical to BI 10773 low dose, BI 10773; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 25
States / cities: Birmingham, Alabama • Tempe, Arizona • Huntington Park, California + 21 more

Conditions: Diabetes Mellitus and Heart Failure
Interventions: LIK066, Placebo, Empagliflozin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 21
States / cities: Huntsville, Alabama • Carmichael, California • Concord, California + 18 more

Conditions: Gout and Hyperuricemia
Interventions: Empagliflozin 10 mg, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Aging, Arterial Stiffness
Interventions: Empagliflozin 10 MG, Placebo; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 60 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Kidney Transplant, Chronic Kidney Disease
Interventions: Empagliflozin; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 19 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 5
States / cities: Hines, Illinois • Iowa City, Iowa • Omaha, Nebraska + 2 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo identical to BI10773 high dose, BI 10773, BI 10773 open label, Placebo identical to BI10773 low dose, Placebo identical to Sitagliptin 100mg, BI10773, Sitagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 986 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 27
States / cities: Mesa, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 23 more

Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: Empagliflozin 10 MG, Placebo Oral Tablet; Drug
Lead sponsor: Justin Ryder; Other
Eligibility: 16 Years to 20 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes Mellitus, Type 2, Hypertension
Interventions: Empagliflozin low dose, placebo, Empagliflozin high dose; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 92
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 62 more

Conditions: Thrombosis
Interventions: Sotagliflozin, Empagliflozin; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Polypill for Prevention of Cardiomyopathy

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

Polypill Strategy for Heart Failure With Reduced Ejection Fraction

Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

SGLTi, Hepatic Glucose Production and Ketogenesis

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Vascular Effects of SGLT2i in Non-diabetic CKD

SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia

Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial

Empagliflozin Reversal of Arterial StiffnEss in Aging

Empagliflozin Treatment in Kidney Transplant Recipients

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Antithrombotic Activities of Sotagliflozin vs. Empagliflozin